Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes duo: new combo shot shows promise for blood sugar

NCT ID NCT04982575

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining two injectable drugs, cagrilintide and semaglutide, works better than either drug alone for lowering blood sugar in people with type 2 diabetes. 92 adults with type 2 diabetes and a BMI of 27 or higher took part. Participants received weekly injections of either the combo or one drug plus a placebo for 32 weeks. The main goal was to see how much HbA1c (a blood sugar measure) dropped from start to week 32.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cagrilintide and semaglutide (injectable drugs)
What this could lead to
If it works, this combination could offer better blood sugar control for people with type 2 diabetes than either drug alone.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 92 participants. Results may not apply to everyone, and side effects or lack of added benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

92 people

The number who actually took part.

Started

Aug 2021

Finished

Jul 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female of non-childbearing potential or male * Age above or equal to 18 years at the time of signing informed consent * Body mass index (BMI) greater than or equal to 27.0 kg/m\^2 * Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening * Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening * Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at maximum tolerated or effective dose as judged by the investigator: metformin with or without Sodium-glucose co-transporter-2 (SGLT2) inhibitor Exclusion Criteria: * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed * Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 60 ml/min/1.73m\^2 by central laboratory at screening * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502, United States

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida, 33324, United States

  • DCOL Ctr for Clin Res

    Longview, Texas, 75605, United States

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • Ellipsis Group

    Alpharetta, Georgia, 30022, United States

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California, 91978, United States

  • FPA Clinical Research

    Kissimmee, Florida, 34741, United States

  • Florida Inst For Clin Res

    Orlando, Florida, 32825, United States

  • Holston Medical Group

    Kingsport, Tennessee, 37660, United States

  • Lillestol Research LLC

    Fargo, North Dakota, 58104, United States

  • MD Medical Research

    Oxon Hill, Maryland, 20745, United States

  • Macoupin Research Group

    Gillespie, Illinois, 62033, United States

  • New West Physicians,Inc.

    Golden, Colorado, 80401, United States

  • Pacific Clinical Studies

    Los Alamitos, California, 90720, United States

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • Plains Clinical Research Center, LLC_Fargo

    Fargo, North Dakota, 58104, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Uni of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • Valley Research

    Fresno, California, 93720, United States

  • Velocity Clin Res Los Angeles

    Los Angeles, California, 90017, United States

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.